AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17919489
Drug: HCV-specific CD8
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV-specific CD8 T-cell responses during the first weeks of therapy
Trial: 17919489
Drug: Late treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late treatment phase T-cell responses
Trial: 11570617
Drug: Zafirlukast, 20
RxNorm normalized name: Zafirlukast, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast, 20 mg twice daily
Trial: 9924306
Drug: Prophylactic laser
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic laser treatment (argon green laser, approximately 100 mild laser burns)
Trial: 31585796
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 500 mL of crystalloid solution
Trial: 28095397
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment utility (OTU)
Trial: 25769361
Drug: Higher-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose edoxaban (60 mg once daily)
Trial: 25769361
Drug: Lower-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose edoxaban (30 mg once daily)
Trial: 25769361
Drug: Warfarin (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (dose adjusted to INR 2.0-3.0)
Trial: 19996654
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral EMP 10 mg/kg in 3 doses
Trial: 19996654
Drug: Low-dose EMP
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose EMP 3 mg/kg once daily plus VP16 25 mg/m(2) once daily on days 1 through 14
Trial: 16335163
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded TiUnite implants
Trial: 16335163
Drug: Brånemark implants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brånemark implants (control)
Trial: 12077735
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus 1 mg hydroxocobalamin administered subcutaneously once per week after dialysis
Trial: 12077735
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (5 to 6 mg folic acid, 5 to 10 mg pyridoxine, and 6 to 10 microg oral vitamin B(12) per day)
Trial: 9860110
Drug: Morphine 40
RxNorm normalized name: morphine 40 mg/12 to 24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 40 mg
Trial: 219964
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (13 courses of three infusions over 3 years, each infusion containing 12 mg/kg cyclophosphamide, 12 mg/kg 5‐fluorouracil, 0.5 mg/kg methotrexate, 0.1 mg/kg vinblastine)
Trial: 30336181
Drug: Adalimumab in
RxNorm normalized name: adalimumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab in combination with methotrexate (20 or 40 mg, according to body weight)
Trial: 30336181
Drug: Methotrexate alone
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate alone (up to 25 mg weekly)
Trial: 17143593
Drug: Pectoral stretching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectoral stretching program (daily low-load, prolonged stretches)
Trial: 14730599
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine) plus prednisolone
Trial: 14730599
Drug: Single therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single therapy with a DMARD with or without prednisolone
Trial: 12575592
Drug: Antibiotics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics plus Chinese drugs combined treatment
Trial: 12575592
Drug: Simple antibiotics
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple antibiotics treatment
Trial: 9456641
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine digluconate (Peridex) mouthrinses, twice daily for 6 days per week, supervised for 3 months
Trial: 9456641
Drug: Placebo mouthrinses,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouthrinses, twice daily for 6 days per week, supervised for 3 months
Trial: 29396738
Drug: Genetic-guided warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic-guided warfarin arm (GEN)
Trial: 26603056
Drug: Nintedanib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 200 mg twice daily plus Best Supportive Care (BSC)
Trial: 7584746
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (ALB) 2.5 mg
Trial: 7584746
Drug: Subcutaneous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous terbutaline (TERB) 0.25 mg
Trial: 6932207
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg PG F2α
Trial: 6932207
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg PG F2α
Trial: 6932207
Drug: Combined prostaglandin-treated
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined prostaglandin-treated group (25 mg and 50 mg PG F2α)
Trial: 27568072
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation (800mg calcium and 400IU vitamin D daily, n=8)
Trial: 26525550
Drug: Fast-track surgery
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-track surgery combined with Chinese medicine treatment
Trial: 23351578
Drug: Wax-matrix extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wax-matrix extended-release niacin (WMER) 1500 mg/d
Trial: 23351578
Drug: Inositol hexanicotinate
RxNorm normalized name: Inositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol hexanicotinate (IHN) 1500 mg/d
Trial: 18801639
Drug: Self-help treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-help treatment (book and 6 weeks of DVD or videotape)
Trial: 11403176
Drug: Pilocarpine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (5 mg three times per day starting the day before radiation therapy)
Trial: 8933126
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g of raw ginger root daily for two weeks
Trial: 8933126
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g of cooked stem ginger daily for two weeks
Trial: 4064546
Drug: 50.0 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50.0 Gy in 20 daily fractions
Trial: 4064546
Drug: 52.5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 52.5 Gy in 20 daily fractions
Trial: 4064546
Drug: 57.5 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 57.5 Gy in 20 daily fractions
Trial: 30032505
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml 12.5% CHO
Trial: 30032505
Drug: 300 ml
RxNorm normalized name: HYQVIA 30 GM / 300 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 ml 12.5% CHO
Trial: 30032505
Drug: 400 ml
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ml 12.5% CHO
Trial: 30032505
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml 12.5% CHO
Trial: 24332514
Drug: Oral ibandronic
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronic acid 50 mg daily
Trial: 24332514
Drug: Intravenous zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid 4 mg every 3-4 weeks
Trial: 20690416
Drug: Maxcem (MA)
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maxcem (MA) with tribochemical treatment
Trial: 20690416
Drug: Smartcem (SM)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Smartcem (SM) with tribochemical treatment
Trial: 20690416
Drug: Rely X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rely X Unicem Aplicap (UN) with tribochemical treatment
Trial: 20690416
Drug: Breeze (BR)
RxNorm normalized name: Halls Breezers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breeze (BR) with tribochemical treatment
Trial: 20690416
Drug: Biscem (BI)
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biscem (BI) with tribochemical treatment
Trial: 20690416
Drug: Set (SE)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Set (SE) with tribochemical treatment
Trial: 20690416
Drug: Clearfil SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clearfil SA luting (CL) with tribochemical treatment
Trial: 16182353
Drug: d-Amphetamine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-Amphetamine (0, 2.5, 5, 10 and 15 mg) alone
Trial: 16182353
Drug: Oxazepam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam (20 mg) + d-Amphetamine (15 mg)
Trial: 2278365
Drug: Etomidate in
RxNorm normalized name: etomidate Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate in lipid emulsion (20 mg in 10 ml of Lipofundin MCT 20%)
Trial: 2278365
Drug: Etomidate in
RxNorm normalized name: etomidate Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate in propylene glycol (35% solution)
Trial: 20170026
Drug: Initiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of therapy for ovarian cancer
Trial: 17710561
Drug: Pharmacist recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist recommendations for drug therapy changes (267 recommendations total)
Trial: 17710561
Drug: Pharmacist recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist recommendations to add a new antihypertensive medication (46.4%) or increase a dose (33.3%)
Trial: 17710561
Drug: Pharmacist recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist recommendations for no change in treatment plan (361 times)
Trial: 9591815
Drug: Tazarotene 0.05%
RxNorm normalized name: TAZAROTENE 0.05% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.05% gel
Trial: 1997933
Drug: Metoclopramide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (3 mg/kg, 15 min i.v.)
Trial: 1997933
Drug: Droperidol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (1.25 mg slow push)
Trial: 30898462
Drug: Physician choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician choice of antibiotic
Trial: 25085298
Drug: Carbon dioxide
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon dioxide laser treatment (beam diameter, 0.2 mm; power, 0.7 W)
Trial: 22147075
Drug: Dacomitinib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib (45 mg) plus Dextromethorphan (DM)
Trial: 17382026
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus EGFR tyrosine kinase inhibitors (gefitinib or erlotinib)
Trial: 15105062
Drug: Triphasic combined
RxNorm normalized name: Tribasic Calcium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic combined oral contraceptive (COC)
Trial: 12192203
Drug: Potential future
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potential future therapies and prophylactic recommendations
Trial: 8130022
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Bendrofluazide + Loop diuretic)
Trial: 8130022
Drug: Prolonged treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged treatment (Bendrofluazide + Loop diuretic)
Trial: 8130022
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Bendrofluazide + Metolazone + Loop diuretic)
Trial: 23303874
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (15 mg daily)
Trial: 29973165
Drug: Individual Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Health Management (IHM) lifestyle program, including access to a web-based health portal and participation in training sessions (3 full-day and 10 two-hour sessions in the first 3 months, followed by 4 training sessions and weekly monitoring for 9 months).
Trial: 26630910
Drug: High-intensity functional
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity functional exercise program (intensive strengthening and balance exercises in small groups twice a week for 12 weeks)
Trial: 24517948
Drug: Continuous-infusion elastomeric
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-infusion elastomeric pump with local anesthetic (LA)
Trial: 16231250
Drug: Dalbavancin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalbavancin (1000 mg IV on day 1 and 500 mg IV on day 8)
Trial: 16231250
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg IV or orally every 12 hours for 14 days)
Trial: 12470424
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion (HAI) of activated leukocytes after stimulation with GM-CSF
Trial: 12470424
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion (HAI) of activated leukocytes after stimulation with IL-2
Trial: 12470424
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HAI of melphalan (50 mg) and activated leukocytes
Trial: 12470424
Drug: HAI of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAI of melphalan (50 mg) alone
Trial: 7864411
Drug: Enalaprilat (0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (0.06 mg/kg)
Trial: 25698370
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept (125 mg/week)
Trial: 28822046
Drug: Intravenous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous abatacept (10 mg/kg/month)
Trial: 28822046
Drug: Subcutaneous and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous and Intravenous abatacept
Trial: 20947593
Drug: Remifentanil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.5 µg kg⁻¹ (R0.5 group, n=24)
Trial: 20947593
Drug: Remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1 µg kg⁻¹ (R1.0 group, n=24)
Trial: 20947593
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of remifentanil
Trial: 15553818
Drug: Compound Salvia
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Salvia injection (CSI) plus conventional treatment of western medicine
Trial: 29546692
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplement of 4000 IU for 3 years
Trial: 19875974
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by adjuvant treatment with tegafur-uracil (UFT)
Trial: 16773286
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation (prep group)
Trial: 16773286
Drug: No mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mechanical bowel preparation (non-prep group)
Trial: 15296809
Drug: Hormone-Replacement Therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone-Replacement Therapy (HRT) component
Trial: 10936836
Drug: Infiltration anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration anesthesia with 3.6 mL of lidocaine with 1:80,000 epinephrine (L-E)
Trial: 2906476
Drug: olsalazine, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olsalazine, 3 g/day
Trial: 2906476
Drug: sulphasalazine, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulphasalazine, 3 g/day
Trial: 28740945
Drug: Whole Body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Body Vibration Exercises twice per week (WBVE2)
Trial: 12372097
Drug: Aloesin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloesin treatment (administered four times a day for 15 days)
Trial: 12372097
Drug: Arbutin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbutin treatment (administered four times a day for 15 days)
Trial: 12372097
Drug: Aloesin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloesin and arbutin cotreatment (administered four times a day for 15 days)
Trial: 12372097
Drug: Aloesin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloesin treatment (dose-dependent)
Trial: 6366138
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment strategy
Trial: 2470000
Drug: Dose reductions
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reductions and interval prolongations
Trial: 1096275
Drug: Prenazone 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenazone 600 mg
Trial: 1096275
Drug: Aspirin 4
RxNorm normalized name: aspirin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 4 g daily
Trial: 31076856
Drug: B-vitamin supplementation
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin supplementation (folic acid 400 µg and vitamin B12 500 µg)
Trial: 27828579
Drug: Cognitive-motor physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-motor physiotherapy intervention (4 months, single weekly visit)
Trial: 25104582
Drug: 3g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g of sea buckthorn (SB) oil daily
Trial: 17963431
Drug: MN 001
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN 001 (750 mg twice daily)
Trial: 17963431
Drug: MN 001
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MN 001 (500 mg three times daily)
Trial: 11449671
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of argatroban (10 mg/day, three times a week)
Trial: 9482129
Drug: verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: verapamil SR 240 mg (V)
Trial: 9482129
Drug: amiloride 5
RxNorm normalized name: amiloride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amiloride 5 mg + hydrochlorothiazide 50 mg (AH)
Trial: 8304488
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion to maintain plasma ANG II levels at around basal values (6.6 ± 1.6 pmol/l)
Trial: 8304488
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of aldosterone (previous study)
Trial: 10077777
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg b.i.d. for 10 days)
Trial: 10077777
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (250 mg b.i.d. for 10 days)
Trial: 7586944
Drug: Buccal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal administration of 5 mg atipamezole hydrochloride